About Aurobindo Antibiotics Private Limited
Data last updated: 06 February 2026
Aurobindo Antibiotics Private Limited is a private limited company based in Vishakhapatnam, Andhra Pradesh, India, a subsidiary of Aurobindo Pharma Ltd. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 06 October 2020, the company has been in operation for over 6 years.
Registered with ROC Vijayawada under CIN U24110AP2020PTC115965.
Capital: an authorised share capital of ₹1 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Sadananda Reddy Sannareddy and Nityananda Reddy Kambam.
Last AGM: 22 September 2025. Financial statements filed for year ended 31 March 2025. Office: Unit 14 Jn Pharma City Plot No 17 Rno.10 11 & 19 20 E Bonangi Vlg, Vishakhapatnam, Andhra Pradesh, India – 531021.
The company has a workforce of approximately 1 employees as per the latest available data. It operates as a subsidiary of Aurobindo Pharma Ltd. Its group structure includes 2 subsidiaries.
For more details, the company can be reached via its website aurobindo.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressUnit 14 Jn Pharma City Plot No 17 Rno.10 11 & 19 20 E Bonangi Vlg, Vishakhapatnam, Andhra Pradesh, India – 531021
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Business Activity of Aurobindo Antibiotics Private Limited
Aurobindo Antibiotics Private Limited operates primarily in the manufacturing sector. The company has 2 registered business activity segments, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| ********* | Manufacturing | ********* | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Aurobindo Antibiotics Private Limited
Aurobindo Antibiotics Private Limited is audited by G P M &ASSOCIATES for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G P M &ASSOCIATES | blur-value | blur-value | blur-value |
Board of Directors of Aurobindo Antibiotics Private Limited
Aurobindo Antibiotics Private Limited is currently managed by 4 directors, with 1 former director having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Sadananda Reddy Sannareddy
Also directs:
Panchatatva Healthcare Llp, Aurozest Private Limited
|
Director | 06 Oct 2020 | 5 Years 9 Months | Current |
|
Nityananda Reddy Kambam
Also directs:
Aurobindo Pharma Ltd, Apl Healthcare Limited, Apitoria Pharma Private Limited and 5 more
|
Director | 26 Dec 2022 | 3 Years 6 Months | Current |
| Gopala Krishna Reddy Penupolu | Director | 06 Oct 2020 | 5 Years 9 Months | Current |
| Bhanu Murthy Chavali | Director | 06 Oct 2020 | 5 Years 9 Months | Current |
Financials of Aurobindo Antibiotics Private Limited FY 2025 filings available
Aurobindo Antibiotics Private Limited reported revenue of ₹- (up ) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Aurobindo Antibiotics Private Limited
As of FY 2023, Aurobindo Antibiotics Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Group Structure of Aurobindo Antibiotics Private Limited
Aurobindo Antibiotics Private Limited has 2 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Aurobindo Antibiotics Private Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Lyfius Pharma Private Limited | U24299AP2020PTC116443 |
**.**%
|
| Qule Pharma Private Limited | U24304AP2020PTC116442 |
**.**%
|
Showing major subsidiaries. Total: 2.
Charges & Borrowings Aurobindo Antibiotics Private Limited
Aurobindo Antibiotics Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Aurobindo Antibiotics Private Limited
View historical data on people associated with Aurobindo Antibiotics Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Aurobindo Antibiotics Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Aurobindo Antibiotics Private Limited
GSTIN & GST Filing Data of Aurobindo Antibiotics Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Aurobindo Antibiotics Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Aurobindo Antibiotics Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Aurobindo Antibiotics Private Limited
MSME Payment Delays by Aurobindo Antibiotics Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Aurobindo Antibiotics Private Limited
Subsidiaries & Group Companies of Aurobindo Antibiotics Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Aurobindo Antibiotics Private Limited with ownership details.
MCA Filings & Documents of Aurobindo Antibiotics Private Limited
MCA Filings & Documents of Aurobindo Antibiotics Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Aurobindo Antibiotics Private Limited
Recent News on Aurobindo Antibiotics Private Limited
Frequently Asked Questions about Aurobindo Antibiotics Private Limited
Aurobindo Antibiotics Private Limited is an active private limited company in the pharma sector based in Vishakhapatnam, Andhra Pradesh, India. It was incorporated on 06 October 2020 (6+ years old) and is registered under CIN U24110AP2020PTC115965. The company has 1 employees.
The current directors of Aurobindo Antibiotics Private Limited are:
The primary industry of Aurobindo Antibiotics Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Aurobindo Antibiotics Private Limited can be reached at the registered office: Unit 14 Jn Pharma City Plot No 17 Rno.10 11 & 19 20 E Bonangi Vlg, Vishakhapatnam, Andhra Pradesh, India – 531021, or through the website aurobindo.com.
The authorised capital is ₹1 Cr, and the paid-up capital is ₹1 Cr.
The company has its registered office at Unit 14 Jn Pharma City Plot No 17 Rno.10 11 & 19 20 E Bonangi Vlg, Vishakhapatnam, Andhra Pradesh, India – 531021.